NCT00444639View on ClinicalTrials.gov

Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

June 30, 2008

Conditions
Prostate Cancer
Interventions
DRUG

Triptorelin (Decapeptyl®)

Two injections of 11.25mg given every 12 weeks

Trial Locations (15)

61717

Ziekenhuis Gelderse Vallei, Ede

1081 HV

Vrije Universiteit Medisch Centrum, Amsterdam

1105 AZ

AMC Amsterdam, Amsterdam

6815 AD

Alysis Zorggroep Loc. Rijnstate, Arnhem

5831 HA

Maasziekenhuis Pantein, Boxmeer

7415 EH Deventer

Deventer Ziekenhuis, Deventer

5664 EH

St. Anna Ziekenhuis Geldrop, Geldrop

2803 HH

Groen Hart Ziekenhuis, Gouda

1213 XZ

Ziekenhuis Hilversum, Hilversum

1642 NP

Westfries Gasthuis Hoorn, Hoorn

2334 CK

Diaconessenhuis Leiden, Leiden

3015 GD

Erasmus MC Rotterdam, Rotterdam

8601 ZK

Antonius Ziekenhuis, Sneek

3584 CX

UMC Utrecht, Utrecht

3331 LZ

Albert Schweitzer Ziekenhuis, Zwijndrecht

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY